Skip to main content
Log in

Low dose lisuride in advanced Parkinson disease

  • Original Articles
  • Published:
The Italian Journal of Neurological Sciences Aims and scope Submit manuscript

Abstract

Lisuride was investigated for therapeutic effects in 19 patients with advanced Parkinson disease, no longer satisfactorily responding to routine L-Dopa therapy. The patients were treated with oral Lisuride (0.6–2.5 mg/die) and L-Dopa. The follow-up was at least 6 months. We noted a significant improvement on the Webster Rating Scale at 1st, 3td and 6th months. Disability and on-off phenomen were reduced. Side effects were few. Lisuride is a valuable tool in this type of patient.

Sommario

L'effetto terapeutico e la tollerabilitá della Lisuride sono stati esaminati in 19 pazienti con morbo di Parkinson avanzato, che non rispondevano in modo soddisfacente alla comune terapia con L-Dopa. I pazienti sono stati trattati con Lisuride per via orale (0.6–2.5 mg/die) ed L-Dopa. Il follow-up é stato come minimo di 6 mesi. É stato notato un miglioramento significativo, usando lo Webster Rating Scale, al primo, terzo e sesto mese di trattamento. Anche l'invaliditá ed i fenomenti a tipo “on-off” sono stati ridotti. Gli effetti collaterali sono stati scarsi. La Lisuride é efficace in tale genere di pazienti.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Birkmayer W., Riederer P.:Effects of Lisuride on motor functions, psychomotor activity and psychic behaviour in Parkinson Disease. In Lisuride and other Dopamine Agonists. Calne DB et al, Raven Press, New York, pp. 453–461, 1983.

    Google Scholar 

  2. Canter C.J., De La Torre R., Nier M.:A method of evaluating disability in patients with Parkinson Disease. J. Nerve Mental Dis. 183: 146–147, 1961.

    Google Scholar 

  3. Colton T.:Statistica in medicina. Piccin Editore, pp. 221–223, 1979.

  4. Cote T.E., Esekay R.L., Frey E.A. et al.:Actions of Lisuride on Adrenoreceptors and Dopamine receptors. In Lisuride and other Dopamine agonists. Calne DB et al, Raven Press, New York, pp. 45–33, 1983.

    Google Scholar 

  5. Duvoisin R.C.:The evaluation of extrapyramidal disease. In Monoamine, noyaux gris centraux et syndroxe de Parkinson. Ajuriaggera J, Masson, Paris, pp. 313–325, 1970.

    Google Scholar 

  6. Folstein M.F., Folstein S.E., Mc Hugh P.R.:Mini-mental State: a practical method for grading cognitive state of patients for the clinician. J. Psychiatr. Res. 12:189, 198, 1975.

    Article  CAS  PubMed  Google Scholar 

  7. Frattola L., Albizzati M.G., Bassi S., Ferrarese C., Trabucchi M.:On-off phenomena, dyskinesias and dystonias. Acta Neurol Scand. 66:227–236, 1982.

    CAS  PubMed  Google Scholar 

  8. Hoehn M.M., Yahr M.D.:Parkinsonism: onset, progression and mortality. Neurology 17: 427–442, 1969.

    Google Scholar 

  9. Horowski R.:Differences in the dopaminergic effects of the Ergot Derivatives-Bromocriptine, Lisuride and D-LSD as compared with Apomorfine. Eur. J. Pharmacol. 51:157–166, 1978.

    Article  CAS  PubMed  Google Scholar 

  10. Lieberman A.N., Goldstein M., Neophytides A et al..Lisuride in Parkinson Disease: efficacy of Lisuride compared to L-Dopa. Neurology 31:961–965, 1981.

    CAS  PubMed  Google Scholar 

  11. Lieberman A.N., Goldstein M., Leibowitz M. et al:Lisuride combined with L-Dopa in advanced Parkinson Disease. Neurology 31:1466/1469, 1981.

    Google Scholar 

  12. Kebahian J.W., Calne D.B.:Multiple receptors for Dopamine. Nature 277:93–96, 1979.

    Google Scholar 

  13. Marson C.D.:Success and problems on Long term L-Dopa therapin Parkinson Disease Lancet i, 346–349, 1977.

    Google Scholar 

  14. Meneghetti G., Bbracco F., Giometto B., Ferla S., Schernia E.:Therapeutic effect of Lisuride in advanced Parkinson's Disease. Eur. Neurol. 25: 74–80, 1986.

    CAS  PubMed  Google Scholar 

  15. Obeso J.A., Lunquin M.R., Martinez-Lage J.M.:Lisuride infusion for Parkinson Disease. Ann. Neurol. 14: 134, 1983.

    Article  Google Scholar 

  16. Obeso J.A., Lunquin M.R., Martinez-Lage Y.M.:Intravenous Lisuride corrects oscillations of motor performace in Parkinson Disease. Ann. Neurol. 19:31–35, 1986.

    CAS  PubMed  Google Scholar 

  17. Obeso J.A.:Continous dopaminergic stimulation: Lisuride infusion. In Atti del IV European workshop on clinical neuropharmacology. Pamplona, Spagna, pp. 38, 1986.

    Google Scholar 

  18. Parkes J.D., Schahter M., Marsden C.D., Smith B., Wilson A.:Lisuride in Parkinsonism. Ann. Neurol. 9:48–52, 1981.

    Article  CAS  PubMed  Google Scholar 

  19. Rinne U.K.:New Ergot Derivatives in treatment of Parkinson's Disease. in Lisuride and Other Dopamine Agonists. Calne D.B. et al, Raven Press, New York, pp. 431–442, 1983.

    Google Scholar 

  20. Wabster D.D.:Critical analysis of the disability of Parkinson Disease. Mod. Treat. 5: 257–287, 1968.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Degl'Innocenti, F., Ginanneschi, A., Magnolfi, S. et al. Low dose lisuride in advanced Parkinson disease. Ital J Neuro Sci 8, 351–355 (1987). https://doi.org/10.1007/BF02335738

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02335738

Key-Words

Navigation